- Home
- SGRP vs CUE Comparison
SGRP vs CUE Comparison
Compare SGRP & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGRP | CUE |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 17.6M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SGRP | CUE |
|---|---|---|
| Price | $0.73 | $21.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 54.9K | ★ 814.5K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $136,104,000.00 | $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.50 | $0.17 |
| 52 Week High | $1.41 | $41.42 |
Technical Indicators
Market Signals| Indicator | SGRP | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 53.74 |
| Support Level | $0.74 | $0.30 |
| Resistance Level | $0.80 | $41.42 |
| Average True Range (ATR) | 0.04 | 3.02 |
| MACD | 0.01 | -1.42 |
| Stochastic Oscillator | 99.82 | 22.84 |
Price Performance
Historical ComparisonAbout SGRP SPAR Group Inc.
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. The company provides five principal types of services: Merchandising, Marketing and Category Management, Remodel and Retail Transformation, Assembly and Installation, Fulfilment and Distribution, and Business Analytics and Insights. It operates in two segments, namely the U.S. and Canada, with the majority of the revenues deriving from the U.S. segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.